TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

J&J wins U.S. approval for TB tablet

Email Newsletters

Click here to sign up for one of our email newsletters.

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

JNJ $70.10 +$0.62

at close on MONDAY

By Anna Edney C.2012 Bloomberg News
Monday, Dec. 31, 2012, 10:30 p.m.
 

Johnson & Johnson won regulatory approval for its tuberculosis tablet Sirturo, the first drug in 40 years that provides a new way to treat the contagious lung infection.

The Food and Drug Administration cleared Sirturo to be added to therapies for use by adults whose illness is resistant to multiple medicines, the New Brunswick, N.J.- based company said Monday.

While tuberculosis was once the leading cause of death in the nation, the drug-resistant version of the illness affected about 98 people last year, according to the Centers for Disease Control and Prevention.

Subscribe today! Click here for our subscription offers.

 

 


Show commenting policy

Most-Read Business Headlines

  1. Hog Father’s eatery chain ferries barbecue to workers at gas well pads
  2. Stocks slide in busy week of quarterly earnings reports
  3. Starbucks glitch that closed stores shows reliance on registers
  4. Mylan rejects Teva’s $40 billion takeover bid
  5. Mixed economy likely means no Fed rate hike soon
  6. ESPN sues Verizon over unbundling plan for FiOS
  7. Oil’s rebound pushes up price at gas pumps
  8. Nike, Under Armour invest in watching exercisers’ steps
  9. Retailers vie for workers in tightening labor market
  10. Pittsburgh area home prices climb in first quarter
  11. Low average of jobless claims points to hiring rebound